These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 11884203

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL, Aharony D, Bialecki RA, Abbott BM, Barthlow HG, Caccese R, Ghanekar S, Lengel D, McCarthy M, Wenrich B, Undem B, Ohnmacht C, Shenvi A, Albert JS, Brown F, Bernstein PR, Russell K.
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.
    Cirillo R, Astolfi M, Conte B, Lopez G, Parlani M, Terracciano R, Fincham CI, Manzini S.
    Eur J Pharmacol; 1998 Jan 12; 341(2-3):201-9. PubMed ID: 9543241
    [Abstract] [Full Text] [Related]

  • 6. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C, Tramontana M, Patacchini R, Lecci A, Catalani C, Catalioto RM, Meini S, Valenti C, Altamura M, Giuliani S, Maggi CA.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):140-8. PubMed ID: 16979621
    [Abstract] [Full Text] [Related]

  • 7. Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible "septide-selective" receptors in guinea pig bronchus.
    Zeng XP, Burcher E.
    J Pharmacol Exp Ther; 1994 Sep 07; 270(3):1295-300. PubMed ID: 7523658
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM, Shatzer SA, Knippenberg RW, Logan DE, Poirot M, van Giersbergen PL, Burkholder TP.
    J Pharmacol Exp Ther; 1996 May 07; 277(2):840-51. PubMed ID: 8627566
    [Abstract] [Full Text] [Related]

  • 10. Bronchoconstrictor effect of the tachykinin NK₃-receptor agonists [MePhe⁷]-neurokinin B and senktide in the isolated guinea pig lung.
    Corboz MR, Rivelli MA, Eckel SP.
    Exp Lung Res; 2010 Nov 07; 36(9):509-21. PubMed ID: 20939761
    [Abstract] [Full Text] [Related]

  • 11. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
    Patacchini R, Quartara L, Astolfi M, Goso C, Giachetti A, Maggi CA.
    J Pharmacol Exp Ther; 1995 Mar 07; 272(3):1082-7. PubMed ID: 7891319
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H, Takahashi S, Nosaka E, Mukaiyama O, Yamashita M, Morimoto K.
    Eur J Pharmacol; 2008 May 31; 586(1-3):306-12. PubMed ID: 18353309
    [Abstract] [Full Text] [Related]

  • 15. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    Nordquist RE, Durkin S, Jacquet A, Spooren W.
    Eur J Pharmacol; 2008 Dec 14; 600(1-3):87-92. PubMed ID: 18930726
    [Abstract] [Full Text] [Related]

  • 16. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376.
    Maggi CA, Giuliani S, Ballati L, Lecci A, Manzini S, Patacchini R, Renzetti AR, Rovero P, Quartara L, Giachetti A.
    J Pharmacol Exp Ther; 1991 Jun 14; 257(3):1172-8. PubMed ID: 1710662
    [Abstract] [Full Text] [Related]

  • 17. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
    Juszczak M, Boczek-Leszczyk E, Stempniak B.
    J Physiol Pharmacol; 2007 Dec 14; 58(4):829-43. PubMed ID: 18195491
    [Abstract] [Full Text] [Related]

  • 18. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
    Anthes JC, Chapman RW, Richard C, Eckel S, Corboz M, Hey JA, Fernandez X, Greenfeder S, McLeod R, Sehring S, Rizzo C, Crawley Y, Shih NY, Piwinski J, Reichard G, Ting P, Carruthers N, Cuss FM, Billah M, Kreutner W, Egan RW.
    Eur J Pharmacol; 2002 Aug 23; 450(2):191-202. PubMed ID: 12206858
    [Abstract] [Full Text] [Related]

  • 19. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
    Ricciardolo FL, Trevisani M, Geppetti P, Nadel JA, Amadesi S, Bertrand C.
    Br J Pharmacol; 2000 Mar 23; 129(5):915-20. PubMed ID: 10696090
    [Abstract] [Full Text] [Related]

  • 20. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
    Miike T, Shirahase H, Kanda M, Kunishiro K, Kurahashi K.
    Vascul Pharmacol; 2009 Mar 23; 51(2-3):147-53. PubMed ID: 19539781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.